Non-intravenous carbapenem-sparing antibiotics for the definitive treatment of bacteremia due to Enterobacteriaceae-producing ESBL or AmpC β-lactamase. A propensity score study.
Sign Up to like & getrecommendations! Published in 2019 at "International journal of antimicrobial agents"
DOI: 10.1016/j.ijantimicag.2019.05.004
Abstract: BACKGROUND Carbapenems are considered the treatment of choice for extended-spectrum β-lactamase (ESBL) or AmpC β-lactamase-producing Enterobacteriaceae bacteremia. Data on the effectiveness of non-intravenous carbapenem-sparing antibiotic options are limited. OBJECTIVE To compare the 30 day-mortality and… read more here.
Keywords: treatment; bacteremia; esbl ampc; carbapenem sparing ... See more keywords